Northland Securities Sticks to Their Buy Rating for MiMedx Group (MDXG)
Northland Securities analyst Carl Byrnes maintained a Buy rating on MiMedx Group today and set a price target of $12.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Byrnes covers the Healthcare sector, focusing on stocks such as Alvotech, Brainsway, and BioLife Solutions. According to TipRanks, Byrnes has an average return of -4.1% and a 36.78% success rate on recommended stocks.
In addition to Northland Securities, MiMedx Group also received a Buy from TR | OpenAI – 4o’s Dex Genotek in a report issued yesterday. However, on October 30, TR | OpenAI – 4o reiterated a Hold rating on MiMedx Group (NASDAQ: MDXG).
Based on MiMedx Group’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $113.73 million and a net profit of $16.75 million. In comparison, last year the company earned a revenue of $84.06 million and had a net profit of $8.1 million
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDXG in relation to earlier this year. Earlier this month, Kimberly Maersk-Moller, the CCO of MDXG sold 58,300.00 shares for a total of $432,003.00.
Read More on MDXG:
